secwatch.observer — SEC 8-K summary
======================================

Issuer:     CUMBERLAND PHARMACEUTICALS INC (CPIX)
CIK:        0001087294
Form:       8-K
Filed at:   2022-11-08T23:59:59+00:00
Accession:  0001628280-22-028987
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cumberland Q3 revenue up 41% to $11.4M; net loss narrows to $0.4M
-----------------------------------------------------------------

- Net revenue $11.4M vs $8.1M a year ago, driven by Sancuso ($4.0M) and Kristalose ($3.9M).
- Net loss improved to $0.4M from $1.1M; adjusted earnings $1.4M ($0.10/share).
- Year-to-date cash from operations $5.6M, up 28% from $4.4M.
- Completed Sancuso transition under co-promotion with Verity; RediTrex amendment allows Nordic to assume U.S. commercialization after March 2023.
- Phase II ifetroban trials ongoing; AERD study closed to enrollment awaiting top-line results.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/0001628280-22-028987-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1087294/000162828022028987/cpix-20221108.htm
  HTML page:      https://secwatch.observer/filing/0001628280-22-028987

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer